CN116570560A - Dexamethasone sodium phosphate injection and preparation method thereof - Google Patents
Dexamethasone sodium phosphate injection and preparation method thereof Download PDFInfo
- Publication number
- CN116570560A CN116570560A CN202310788479.9A CN202310788479A CN116570560A CN 116570560 A CN116570560 A CN 116570560A CN 202310788479 A CN202310788479 A CN 202310788479A CN 116570560 A CN116570560 A CN 116570560A
- Authority
- CN
- China
- Prior art keywords
- sodium phosphate
- injection
- dexamethasone sodium
- filling
- chelating agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 title claims abstract description 34
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 title claims abstract description 34
- 238000002347 injection Methods 0.000 title claims abstract description 26
- 239000007924 injection Substances 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 238000011049 filling Methods 0.000 claims abstract description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000008215 water for injection Substances 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 239000002738 chelating agent Substances 0.000 claims abstract description 14
- 230000003204 osmotic effect Effects 0.000 claims abstract description 13
- 238000003756 stirring Methods 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 10
- 238000007789 sealing Methods 0.000 claims abstract description 10
- 230000001954 sterilising effect Effects 0.000 claims abstract description 10
- 239000007788 liquid Substances 0.000 claims abstract description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 9
- 238000005303 weighing Methods 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 239000003708 ampul Substances 0.000 claims abstract description 6
- 239000005388 borosilicate glass Substances 0.000 claims abstract description 6
- 238000001914 filtration Methods 0.000 claims abstract description 6
- 230000001105 regulatory effect Effects 0.000 claims abstract description 6
- 238000005429 filling process Methods 0.000 claims abstract description 3
- 238000002156 mixing Methods 0.000 claims abstract description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- 239000011780 sodium chloride Substances 0.000 claims description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical group [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229940124274 edetate disodium Drugs 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical group [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000289690 Xenarthra Species 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses dexamethasone sodium phosphate injection and a preparation method thereof, comprising the following steps: weighing: weighing dexamethasone sodium phosphate bulk drug, osmotic pressure regulator, chelating agent and pH value regulator according to the prescription amount; dispensing: adding 80% of the prescription amount of water for injection into a container, filling nitrogen for protection in the preparation process, sequentially adding an osmotic pressure regulator, a chelating agent, raw materials and water for injection, stirring for dissolving, regulating pH by using a pH value regulator, adding water for injection for constant volume, and stirring and mixing until uniformity; and (3) sterilizing and filtering: filtering the liquid medicine through a 0.22 mu m sterilizing filter element; and (3) filling and sealing: filling the materials into a borosilicate glass ampoule according to the filling amount, sealing, and filling nitrogen for protection in the filling process. The stability and the safety of the dexamethasone sodium phosphate injection product are improved on the premise of ensuring the effectiveness of the dexamethasone sodium phosphate injection.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to dexamethasone sodium phosphate injection and a preparation method thereof.
Background
Dexamethasone sodium phosphate is white to yellowish powder, odorless and moisture-absorbing. Dexamethasone is a steroid drug, and corticosteroids are hormones naturally occurring in the human body that help maintain health. Dexamethasone reduces inflammation and inhibits the immune system when injected into veins or muscles, and is an effective method for treating various diseases associated with inflammation in the body.
In the products on the market at present, in order to improve the stability of the products, the organic solvent propylene glycol is often added, but researches show that the products have hemolysis and are not suitable for intravenous injection.
Disclosure of Invention
The invention aims to solve the defects in the prior art, and provides a dexamethasone sodium phosphate injection and a preparation method thereof, which improve the stability and safety of a dexamethasone sodium phosphate injection product on the premise of ensuring the effectiveness of the dexamethasone sodium phosphate injection.
In order to achieve the above purpose, the present invention adopts the following technical scheme:
a dexamethasone sodium phosphate injection comprising: dexamethasone sodium phosphate raw material and pharmaceutically acceptable auxiliary materials;
the pharmaceutically acceptable auxiliary materials comprise an osmotic pressure regulator, a chelating agent, a pH value regulator and water for injection.
Preferably, the osmotic pressure regulator is composed of one or more of sodium chloride, glycerol, glucose and mannitol.
Preferably, the chelating agent is disodium edentate.
Preferably, the pH regulator consists of one or more of sodium hydroxide, hydrochloric acid and phosphoric acid.
The invention also provides a preparation method of the dexamethasone sodium phosphate injection, which comprises the following steps:
(1) Weighing: weighing dexamethasone sodium phosphate bulk drug, osmotic pressure regulator, chelating agent and pH value regulator according to the prescription amount;
(2) Dispensing: adding 80% of the prescription amount of water for injection into a container, filling nitrogen for protection in the preparation process, sequentially adding an osmotic pressure regulator, a chelating agent, raw materials and water for injection, stirring for dissolving, regulating pH by using a pH value regulator, adding water for injection for constant volume, and stirring and mixing until uniformity;
(3) And (3) sterilizing and filtering: filtering the liquid medicine through a 0.22 mu m sterilizing filter element;
(4) And (3) filling and sealing: filling the materials into a borosilicate glass ampoule according to the filling amount, sealing, and filling nitrogen for protection in the filling process.
Preferably, the mass ratio of the dexamethasone sodium phosphate bulk drug to the osmotic pressure regulator to the chelating agent is 5:9:10.
Preferably, the formulation process temperature is below 40 ℃.
Preferably, the pH is adjusted to 7.0 to 8.5.
The technical scheme of the invention has the following advantages:
1. the dexamethasone sodium phosphate injection provided by the invention effectively increases the stability of the dexamethasone sodium phosphate injection through the synergistic effect of the osmotic pressure regulator, the chelating agent, the pH value regulator and the dexamethasone sodium phosphate raw material;
2. the preparation method of the dexamethasone sodium phosphate injection is simple and easy to control, and the stability and safety of the dexamethasone sodium phosphate injection product are improved on the premise of ensuring the effectiveness of the dexamethasone sodium phosphate injection by sterilizing and filling and sealing the injection under the protection of nitrogen after adding the effective components for dispensing.
Detailed Description
The following description of the technical solutions in the embodiments of the present invention will be clear and complete, and it is obvious that the described embodiments are only some embodiments of the present invention, but not all embodiments.
Example 1
The preparation process comprises the following steps of
(1) The raw materials and the auxiliary materials are weighed according to the prescription dosage.
(2) Weighing 80% of water for injection in a container, controlling the dispensing temperature below 40 ℃, adding sodium chloride in a prescription amount, and stirring until the sodium chloride is dissolved; adding the raw materials with the prescription amount, and stirring until the raw materials are dissolved; then the pH value of the liquid medicine is regulated to 7.0 to 8.5 by using a pH value regulator, water for injection is added for constant volume, and the mixture is stirred and mixed until uniform.
(3) The liquid medicine was sterilized and filtered using a 0.22 μm sterilizing filter cartridge.
(4) And (5) filling and sealing the borosilicate glass ampoule in use.
Example 2
The preparation process comprises the following steps of
(1) The raw materials and the auxiliary materials are weighed according to the prescription dosage.
(2) Weighing 80% of water for injection in a container, controlling the dosage temperature below 40 ℃, adding the prescribed amount of sodium chloride and edetate disodium, and stirring until the sodium chloride and edetate disodium are dissolved; adding the raw materials with the prescription amount, and stirring until the raw materials are dissolved; then the pH value of the liquid medicine is regulated to 7.0 to 8.5 by using a pH value regulator, water for injection is added for constant volume, and the mixture is stirred and mixed until uniform.
(3) The liquid medicine was sterilized and filtered using a 0.22 μm sterilizing filter cartridge.
(4) And (5) filling and sealing the borosilicate glass ampoule in use.
Example 3
The preparation process comprises the following steps of
(1) The raw materials and the auxiliary materials are weighed according to the prescription dosage.
(2) Weighing 80% of water for injection in a container, controlling the dosage temperature below 40 ℃, adding the prescribed amount of sodium chloride and edetate disodium, and stirring until the sodium chloride and edetate disodium are dissolved; adding the raw materials with the prescription amount, and stirring until the raw materials are dissolved; then the pH value of the liquid medicine is regulated to 7.0 to 8.5 by using a pH value regulator, water for injection is added for constant volume, and the mixture is stirred and mixed until uniform.
(3) The liquid medicine was sterilized and filtered using a 0.22 μm sterilizing filter cartridge.
(4) And (3) filling nitrogen for protection in the filling and sealing process of the borosilicate glass ampoule.
Samples prepared in examples 1 to 3 were placed at a high temperature of 40℃and sampled for 0 day, 5 days, 10 days, and 30 days, respectively, and the properties, pH values, and related substances were measured, and the obtained data are shown in Table 1.
Table 1 test data for examples 1 to 3
Note that: NA indicates that no detection was performed.
Conclusion: the stability of the finished product prepared according to example 3 is remarkably improved compared with other examples when the finished product is examined at a high temperature of 40 ℃, which shows that the stability of the finished product can be remarkably improved by adding the chelating agent during the preparation of dexamethasone sodium phosphate injection and adding nitrogen in the preparation process.
The foregoing is only a preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art, who is within the scope of the present invention, should make equivalent substitutions or modifications according to the technical scheme of the present invention and the inventive concept thereof, and should be covered by the scope of the present invention.
Claims (8)
1. A dexamethasone sodium phosphate injection, comprising: dexamethasone sodium phosphate raw material and pharmaceutically acceptable auxiliary materials;
the pharmaceutically acceptable auxiliary materials comprise an osmotic pressure regulator, a chelating agent, a pH value regulator and water for injection.
2. The dexamethasone sodium phosphate injection as claimed in claim 1, wherein the osmotic pressure regulator is composed of one or more of sodium chloride, glycerol, glucose, mannitol.
3. The dexamethasone sodium phosphate injection as defined in claim 1, wherein the chelating agent is disodium edetate.
4. The dexamethasone sodium phosphate injection as claimed in claim 1, wherein the pH regulator is composed of one or more of sodium hydroxide, hydrochloric acid and phosphoric acid.
5. The preparation method of dexamethasone sodium phosphate injection according to any one of claims 1-4, comprising the following steps:
(1) Weighing: weighing dexamethasone sodium phosphate bulk drug, osmotic pressure regulator, chelating agent and pH value regulator according to the prescription amount;
(2) Dispensing: adding 80% of the prescription amount of water for injection into a container, filling nitrogen for protection in the preparation process, sequentially adding an osmotic pressure regulator, a chelating agent, raw materials and water for injection, stirring for dissolving, regulating pH by using a pH value regulator, adding water for injection for constant volume, and stirring and mixing until uniformity;
(3) And (3) sterilizing and filtering: filtering the liquid medicine through a 0.22 mu m sterilizing filter element;
(4) And (3) filling and sealing: filling the materials into a borosilicate glass ampoule according to the filling amount, sealing, and filling nitrogen for protection in the filling process.
6. The preparation method of dexamethasone sodium phosphate injection according to claim 5, wherein the mass ratio of the dexamethasone sodium phosphate bulk drug to the osmotic pressure regulator to the chelating agent is 5:9:10.
7. The method for preparing dexamethasone sodium phosphate injection according to claim 5, wherein the temperature in the preparation process is below 40 ℃.
8. The method for preparing dexamethasone sodium phosphate injection according to claim 5, wherein the pH value is adjusted to 7.0-8.5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310788479.9A CN116570560A (en) | 2023-06-30 | 2023-06-30 | Dexamethasone sodium phosphate injection and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310788479.9A CN116570560A (en) | 2023-06-30 | 2023-06-30 | Dexamethasone sodium phosphate injection and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116570560A true CN116570560A (en) | 2023-08-11 |
Family
ID=87539908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310788479.9A Pending CN116570560A (en) | 2023-06-30 | 2023-06-30 | Dexamethasone sodium phosphate injection and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116570560A (en) |
-
2023
- 2023-06-30 CN CN202310788479.9A patent/CN116570560A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106727278B (en) | A kind of Timoptic-XE agent and preparation method thereof | |
| CN103550143A (en) | Preparation method of levetiracetam injection | |
| CN112439054B (en) | Teriparatide sustained-release gel injection and preparation method thereof | |
| CN102670489B (en) | Ropivacaine hydrochloride sodium chloride injection and preparation method thereof | |
| EP3984524A1 (en) | Ornidazole injection and s-ornidazole injection | |
| CN116570560A (en) | Dexamethasone sodium phosphate injection and preparation method thereof | |
| CN109481459B (en) | Compound electrolyte glucose injection and preparation method thereof | |
| CN113730348B (en) | Dexamethasone sodium phosphate injection and preparation method thereof | |
| CN113952296B (en) | Preparation method of compound sulfamethoxazole injection | |
| CN110200905A (en) | A kind of ambroxol hydrochloride composition and its injection and application | |
| CN109125256B (en) | Prednisolone injection and preparation method thereof | |
| CN106138211A (en) | A kind of medicinal composition for injections improving Radix Illicii Lanceolati drug injection preparation stability | |
| CN115634196B (en) | Stable-quality anisodine hydrobromide injection and preparation method thereof | |
| CN108158989B (en) | Ambroxol hydrochloride injection composition | |
| CN118403008A (en) | Vitamin B6 injection and preparation method thereof | |
| CN107303267B (en) | Preparation method of clear and stable levo-oxiracetam injection | |
| CN113952294A (en) | Zoledronic acid injection and preparation method thereof | |
| CN103920154B (en) | Tetracaine hydrochloride pharmaceutical composition for injection and preparation method of pharmaceutical composition | |
| CN111184687A (en) | Oxytocin injection and preparation method thereof | |
| CN107753571A (en) | A kind of medicinal composition for injections of decumbent corydalis tuber | |
| CN116850139A (en) | Mequindox injection and preparation method thereof | |
| CN104906127A (en) | Povidone iodine compound preparation with enhanced available iodine content stability and preparation method thereof | |
| CN115105466A (en) | Noradrenaline bitartrate injection and preparation method thereof | |
| CN117357475A (en) | Be used for improving coenzyme Q 10 Stable compositions and uses thereof | |
| CN110538142A (en) | Anti-infective drug injection composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |